{'fraction_non_alphanumeric': 0.023316062176165803, 'fraction_numerical': 0.0025906735751295338, 'mean_word_length': 5.897321428571429, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Quality of life measurement in vitiligo. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes with external experts

Members of the European Academy of Dermatology and Venereology (EADV) Task Force on Quality of Life (QoL) and Patient Oriented Outcomes reviewed the instruments available for health‐related (HR) QoL assessment in vitiligo and together with external vitiligo experts (including representatives of the EADV Vitiligo Task Force) have made practical recommendations concerning the assessment of QoL in vitiligo patients. The Dermatology Life Quality Index (DLQI) was the most frequently used HRQoL instrument, making comparison of results between different countries possible. Several vitiligo‐specific instruments were identified. The vitiligo Impact Scale (VIS) is an extensively validated vitiligo‐specific HRQoL instrument with proposed minimal important change and clinical interpretation for VIS‐22 scores. VIS‐22 was developed for use in India, where there are some specific cultural beliefs concerning vitiligo. The EADV Task Force on QoL and Patient Oriented Outcomes recommends use of the DLQI and the Children's Dermatology Life Quality Index (CDLQI) as dermatology‐specific instruments in vitiligo. There is a strong need for a valid (including cross‐cultural validation) vitiligo‐specific instrument that can be either a new instrument or the improvement of existing instruments. This validation must include the proof of responsiveness.